e-learning
resources
Vienna 2009
Monday, 14.09.2009
Drug effects in COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Association of β2-adrenoreceptor genotype with bronchodilator responses (bdr) in COPD
H. Makita, S. Konno, M. Hasegawa, K. Shimizu, Y. Nasuhara, T. Betsuyaku, M. Nishimura, Hokkaido COPD Cohort Study Group (Sapporo, Japan)
Source:
Annual Congress 2009 - Drug effects in COPD
Session:
Drug effects in COPD
Session type:
Thematic Poster Session
Number:
1998
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Makita, S. Konno, M. Hasegawa, K. Shimizu, Y. Nasuhara, T. Betsuyaku, M. Nishimura, Hokkaido COPD Cohort Study Group (Sapporo, Japan). Association of β2-adrenoreceptor genotype with bronchodilator responses (bdr) in COPD. Eur Respir J 2009; 34: Suppl. 53, 1998
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Association of β
2
-adrenoceptor genotypes with bronchodilatory effect of tiotropium in COPD
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008
Association between genetic polymorphisms of the β2-AR and response to salbutamol in patients with atopic bronchial asthma of Kyrgyz nationality
Source: Eur Respir J 2006; 28: Suppl. 50, 236s
Year: 2006
Association of TNF-α polymorphisms with COPD in a Spanish population
Source: Annual Congress 2010 - Genetics of obstruction
Year: 2010
Association between the GLCCI1 variant and response to inhaled corticosteroids in South Vietnamese asthmatics
Source: International Congress 2018 – Variant forms of asthma
Year: 2018
Respiratory health and endotoxin: associations and modification by CD14/-260 genotype
Source: Eur Respir J 2012; 39: 573-581
Year: 2012
Association between genetic polymorphisms of ADAM33 with asthma and its phenotypes
Source: International Congress 2015 – Genetics and environmental factors in phenotypes of asthma and COPD
Year: 2015
ADRB2R gene polymorphism (pol.) associated with the severity of cystic fibrosis(CF) and the effectiveness of the use of inhaled bronchodilator
Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies
Year: 2010
Relationship between gene polymorphism in FGF10 and susceptibility to 220 patients with COPD
Source: International Congress 2014 – COPD physiopathology
Year: 2014
GLCCI1
variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids
Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD
Year: 2014
VNTR polymorphism in IL1RN gene in COPD and bronchial astma in Bulgarian population
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Haplotypes associated with COPD and its severity in Mexican mestizo population
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
Effect of ADRB2 gene polymorphism on treatment outcomes in asthmatics: Cold airway hyperresponsiveness and asthma control
Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD
Year: 2014
Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines
Source: Eur Respir J, 49 (5) 1700068; 10.1183/13993003.00068-2017
Year: 2017
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
The median number of COPD exacerbations per year in patients with different polymorphisms of the gene ADRB2
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Association between ADAM33 polymorphisms and asthma control
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept